Cargando…
抗肿瘤双特异性抗体研究进展与临床研发关注要点
The drugs of programmed cell death 1 and its ligand 1 immune checkpoint inhibitors have ushered in a new era of anti-tumor immunotherapy, which has shown outstanding efficacy in some tumors, such as Hodgkin lymphoma, but there is still low response rate in some kinds of tumors. In recent years, bisp...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549423/ https://www.ncbi.nlm.nih.gov/pubmed/36172734 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.43 |